Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 10, Issue 5, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-27
DOI
10.1038/s41408-020-0329-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial
- (2019) Jean-Michel Cayuela et al. BLOOD
- SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- (2018) Nicholas J. Short et al. Clinical Lymphoma Myeloma & Leukemia
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
- (2018) Elias Jabbour et al. Lancet Haematology
- Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
- (2017) Ami B. Patel et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
- (2016) Philippe Rousselot et al. BLOOD
- Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis
- (2016) Koji Sasaki et al. CANCER
- Clinical impact ofABL1kinase domain mutations andIKZF1deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665
- (2016) Rebecca DeBoer et al. LEUKEMIA & LYMPHOMA
- Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2015) Farhad Ravandi et al. CANCER
- Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2015) N. Daver et al. HAEMATOLOGICA
- Sequencing small genomic targets with high efficiency and extreme accuracy
- (2015) Michael W Schmitt et al. NATURE METHODS
- The influence of subclonal resistance mutations on targeted cancer therapy
- (2015) Michael W. Schmitt et al. Nature Reviews Clinical Oncology
- Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2015) N. Daver et al. HAEMATOLOGICA
- Detecting ultralow-frequency mutations by Duplex Sequencing
- (2014) Scott R Kennedy et al. Nature Protocols
- Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
- (2013) Simona Soverini et al. LEUKEMIA RESEARCH
- Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
- (2012) Sara Redaelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
- (2012) H Pfeifer et al. LEUKEMIA
- Detection of ultra-rare mutations by next-generation sequencing
- (2012) M. W. Schmitt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2011) R. Foa et al. BLOOD
- Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays
- (2010) C. Cameron Yin et al. CANCER SCIENCE
- 8-Oxo-7,8-dihydroguanine: Links to gene expression, aging, and defense against oxidative stress
- (2010) Zsolt Radak et al. FREE RADICAL BIOLOGY AND MEDICINE
- Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
- (2010) S. Soverini et al. HAEMATOLOGICA
- Mutation Rates and Intrinsic Fidelity of Retroviral Reverse Transcriptases
- (2009) Luis Menéndez-Arias Viruses-Basel
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search